BriaCell (BCTX) Therapeutics announces the addition of a key clinical site, Mayo Clinic, to its ongoing pivotal Phase 3 clinical study in metastatic breast cancer. “We are very excited to be working with renowned clinical experts at a leading cancer center like Mayo Clinic, who also participated in BriaCell’s Phase 2 study,” stated Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We strongly believe that our novel immunotherapy has the potential to transform cancer care for patients and their families.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell’s Bria-IMT Shows Promising Survival Advantage in Metastatic Breast Cancer
- BriaCell announces updated Phase 2 survival data fro Bria-IMT
- Promising Clinical Developments and Positive Outlook Justify Buy Rating for BriaCell Therapeutics
- BriaCell’s Bria-IMT Shows Promising Results in Advanced Breast Cancer Treatment
- BriaCell reports complete, sustained resolution of brain metastasis in patient